Dr Seth Wander from Harvard Medical School in Boston, Massachusetts, discusses mechanisms underlying endocrine resistance in breast cancer and optimal therapeutic approaches for patients who experience disease progression while or after receiving endocrine therapy, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here (https://www.researchtopractice.com/OncologyTodayEndocrineERPosmBC23).